Cancer involves abnormal cells growing uncontrollably, invading nearby tissues, and spreading to other parts of the body through metastasis.
Send us all your questions or requests, and our expert team will assist you.
Ultrasound is the primary imaging modality for the thyroid. It uses high-frequency sound waves to create detailed images of the gland’s structure. Unlike CT or MRI, ultrasound provides exceptional soft-tissue resolution in the neck. When a nodule is identified, the radiologist does not just measure its size; they analyze its architectural features to estimate the risk of malignancy.
This risk estimation is standardized using the Thyroid Imaging Reporting and Data System (TI-RADS). This system assigns points to specific features. Benign features include a sponge-like appearance (spongiform) or being purely fluid-filled (cystic). Suspicious features include the nodule being solid, very dark (hypoechoic), having irregular or jagged margins, possessing microcalcifications (tiny calcium deposits), or being “taller-than-wide” (growing against the tissue planes).
Based on the total score, the nodule is assigned a category (TR1-TR5). TR1 is benign, while TR5 is highly suspicious. This score, combined with the nodule size, dictates the next step. For example, a highly suspicious TR5 nodule might be biopsied if it is over 1 centimeter, whereas a low-risk TR3 nodule might not be biopsied until it grows larger than 2.5 centimeters. This system helps prevent the biopsy of benign nodules.
The definitive diagnosis of a thyroid nodule is achieved through Fine Needle Aspiration (FNA) biopsy. Under ultrasound guidance, a skinny needle is inserted into the nodule to aspirate cells. This procedure is minimally invasive, usually performed without local anesthesia, and carries a very low risk of complications.
The aspirated cells are smeared onto slides and examined by a cytopathologist. The results are reported using the Bethesda System for Reporting Thyroid Cytopathology, which classifies the findings into six diagnostic categories:
This system guides clinical management. Benign nodules are observed. Malignant nodules undergo surgery. The intermediate categories (3 and 4) often pose a clinical dilemma, in which molecular testing is indicated.
Approximately twenty to thirty percent of thyroid biopsies return as “indeterminate” (Bethesda III or IV). Historically, these patients were sent for diagnostic surgery (removal of half the thyroid) to determine what the lump was. Most of the time, the surgery proved unnecessary, as the nodule was benign.
Today, molecular testing has transformed this workflow. If a biopsy is indeterminate, the sample can be analyzed for specific genetic alterations. Tests like the Afirma Gene Expression Classifier or ThyroSeq look for RNA expression patterns or DNA mutations (BRAF, RAS, RET/PTC) that correlate with benign or malignant behavior.
If the molecular test is “benign,” the risk of cancer is very low (similar to a benign biopsy), and the patient can avoid surgery and continue with surveillance. If the test is “suspicious,” the risk of cancer is high, and the surgeon can proceed with a definitive operation, potentially removing the whole thyroid rather than just half, thus avoiding a second surgery.
Thyroid cancer staging follows the TNM system (Tumor, Node, Metastasis), but it has a unique feature not found in other cancers: the profound impact of patient age on prognosis. In Differentiated Thyroid Cancer (Papillary and Follicular), age is a significant staging variable.
For patients under 55 years old, the staging is simplified. If they have no distant metastasis (M0), they are Stage I, regardless of how big the tumor is or if it has spread to lymph nodes. Even with lymph node spread, the survival rate is so high that they remain Stage I. They are only Stage II if they have distant metastasis (M1) to lungs or bones. This group does not have Stage III or IV disease.
In patients 55 years and older, staging behaves similarly to that of typical cancers.
While ultrasound handles the neck, other modalities are needed for advanced staging. A CT scan of the neck and chest with contrast is often used if there is concern that the cancer has invaded deep structures like the retrosternal space (behind the breastbone) or if large lymph nodes are palpable. There was a historical fear of using iodine-based contrast in CT scans for thyroid patients because it interferes with radioactive iodine treatment, but this delay is temporary and manageable.
Whole-Body Scans (WBS) using radioactive iodine (I-123 or I-131) are specific for differentiated thyroid cancer. Because thyroid cells are the only cells that take up iodine, this scan can “light up” metastases in the lungs or bones. This is typically done after the thyroid has been surgically removed to detect residual disease.
FDG-PET scans are reserved for cancers that do not take up iodine (dedifferentiated tumors or anaplastic/medullary cancers). These scans detect metabolic activity (sugar consumption). A tumor that lights up on a PET scan but not on an iodine scan (“flip-flop phenomenon”) is usually more aggressive and requires different treatment.
Send us all your questions or requests, and our expert team will assist you.
A Fine Needle Aspiration (FNA) is generally well-tolerated. It feels similar to a blood draw. The needle used is even smaller than those used for blood tests. Most patients report a sensation of pressure rather than sharp pain. Local anesthesia is often used to numb the skin, making the procedure very manageable.
This falls into Bethesda Category V. It means the pathologist sees cells with the specific features of papillary cancer (such as nuclear grooves or inclusions). Still, the sample isn’t quite perfect enough to say “malignant” with 100% certainty. However, the risk of cancer is 60-75%, and surgery is almost always recommended.
Papillary and follicular thyroid cancers, while usually confined to the neck, can occasionally spread to the lungs. A chest X-ray or CT scan checks for these distant spots (metastases), especially if you have large lymph nodes in your neck or a very invasive primary tumor.
Elastography is a special ultrasound mode that measures the stiffness of a nodule. Malignant tumors tend to be harder and stiffer than healthy thyroid tissue or benign cysts. By gently pressing with the probe, the machine measures how much the nodule deforms. High stiffness increases the suspicion of cancer.
Not necessarily. If you are under 55, you could have a large tumor and positive lymph nodes and still be Stage I. In thyroid cancer, Stage I for young people means “low risk of death,” not necessarily “small amount of disease.” It emphasizes the excellent prognosis for younger patients.
We often see patients with hypothyroidism, a condition where the thyroid gland doesn’t make enough thyroid hormones. The ICD-10 code E03.9 is for “hypothyroidism, unspecified.”
Radioactive iodine (RAI) is a common treatment for Graves’ disease and thyroid cancer. Studies show it doesn’t shorten life for most patients. It might even
Getting the thyroid gland checked right is key to good health. MRI and ultrasound help a lot in checking how well the thyroid is working.
The thyroid gland is a key part of our body, found in the neck. It helps control how our body grows and works. At Liv
At Liv Hospital, we know how important an accurate diagnosis is for your health. A CT scan of the thyroid gland is key. It helps
Understanding Thyroid Gland X-Ray and Ultrasound Knowing the normal size of the thyroid gland is key to detecting issues early. At Liv Hospital, we use
Leave your phone number and our medical team will call you back to discuss your healthcare needs and answer all your questions.
Your Comparison List (you must select at least 2 packages)
